Quarterly report pursuant to Section 13 or 15(d)

Loans Receivable

v3.22.2.2
Loans Receivable
6 Months Ended
Jun. 30, 2022
Loans Receivable  
Loans Receivable

9.Loans Receivable

A breakdown of the loans receivable terms and balances are as follows:

Loans receivable

    

June 30, 2022

    

December 31, 2021

Teneo Fund SPVi LLC note – Interest rate of 18.0% per annum, due on June 1, 2023

$

5,911

$

5,911

Pharma EU, LLC note - Interest rate of 12.0%, due December 31, 2020

1,410

1,410

A&R note - No interest rate, due December 31, 2022

710

714

SSZ and Elev8 note - Interest rate of 8.0% per annum, due on October 8, 2030

1,002

1,002

Pure Hana Synergy note - Interest rate of 10.0% per annum, due August 1, 2022

224

224

Little Beach Harvest note - Interest rate of 9.0% per annum, due August 24, 2036

1,268

423

Total loans receivable

$

10,525

$

9,684

Less allowance for expected credit losses

(6,580)

(5,559)

Loans receivable, net of expected credit losses

3,945

4,125

Less current portion of loan receivable

(2,444)

(2,453)

Loans receivable, long-term

$

1,501

$

1,672

At each reporting date, the Company assesses whether loans receivables are credit impaired by applying the guidance in Accounting Standards Codification (“ASC) 326. A financial asset is considered credit impaired when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. Credit impairment is based on observable data such as significant financial difficulty of the debtor and a breach of contract such as a default or being past due. During the six months ended June 30, 2022, the Company recorded an additional $1,021 of allowance for expected credit losses due to revised collectability estimates.

Current expected credit losses (“CECLs”) are measured by the Company on a probability-weighted basis based on historical experience with losses and forward-looking information, which includes considerations of ongoing legal and regulatory developments in the industry. Loss given default parameters utilized by the Company in estimating CECL generally reflect the assumed recovery rate from underlying collateral, with adjustments for time value of money and estimated costs for obtaining and selling the collateral. Given the repayment profile and underlying terms of such loans, CECLs are generally estimated over the contractual term of the loan.

The following tables present an analysis of the credit quality of loans receivable, together with impairment losses recognized based on lifetime CECLs:

As of June 30, 2022

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

8,891

$

(5,511)

$

3,380

Third party guarantee

1,410

(882)

528

No collateral

224

(187)

37

Net loans receivable

$

10,525

$

(6,580)

$

3,945

As of December 31, 2021

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

8,050

$

(4,556)

$

3,494

Third party guarantee

1,410

(882)

528

No collateral

224

(121)

103

Net loans receivable

$

9,684

$

(5,559)

$

4,125